PRDX1 and cancer: With regard to TNM stage, the results showed the predictive role of PRDX1 positive expression on unfavorable OS in patients with cancer of stages I-IV (HR = 2.03, 95% CI: 1.38-2.98, P < 0.757, random effects), and I (HR = 2.41, 95% CI: 1.29-4.50, P = 0.006, random effects), but not in those with stages I-III (HR = 1.27, 95% CI: 0.77-2.10, P = 0.341, random effects), and none reported (HR = 0.66, 95% CI: 0.50-0.88, P = 0.004, random effects).